Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 9:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 5,775 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bronchial Disease Clear all
Completed Phase 1 Interventional

The Role of Vitamins E and C in Maintaining Lung Health in People With Asthma

NCT00142610
View directory record Official record
Conditions
Asthma
Interventions
Vitamin
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Oct 24, 2026, 9:45 PM EDT
Completed Phase 2 Interventional Results available

LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib

NCT01685060
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
LDK378
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
17
States / cities
Fayetteville, Arkansas • Duarte, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Oct 24, 2026, 9:45 PM EDT
Completed Phase 1Phase 2 Interventional

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

NCT06016088
View directory record Official record
Conditions
Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic, Pseudomonas Aeruginosa
Interventions
RSP-1502, Tobramycin inhalation solution
Drug
Lead sponsor
Respirion Pharmaceuticals Pty Ltd
Industry
Eligibility
12 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
13
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 24, 2026, 9:45 PM EDT
Recruiting Phase 1 Interventional

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

NCT06040541
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Interventions
RMC-9805, RMC-6236
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
17
States / cities
Sacramento, California • New Haven, Connecticut • Sarasota, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 24, 2026, 9:45 PM EDT
Terminated Phase 2 Interventional Results available

Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable - 14X-US-I001

NCT03574818
View directory record Official record
Conditions
Squamous Cell Lung Cancer
Interventions
Necitumumab-Gemcitabine-Cisplatin, Evaluation to determine if patient is a candidate to proceeed with surgical resection or not
Drug · Diagnostic Test
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 24, 2026, 9:45 PM EDT
Recruiting Phase 3 Interventional

A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)

NCT07276724
View directory record Official record
Conditions
Severe Asthma
Interventions
GB-0895, Placebo
Drug
Lead sponsor
Generate Biomedicines
Industry
Eligibility
12 Years to 80 Years
Enrollment
786 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
36
States / cities
Northridge, California • Pasadena, California • Rancho Cucamonga, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 24, 2026, 9:45 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma

NCT01122680
View directory record Official record
Conditions
Asthma
Interventions
tiotropium bromide, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years to 17 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
5
States / cities
Denver, Colorado • Columbia, Missouri • Warrensburg, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 24, 2026, 9:45 PM EDT
Recruiting No phase listed Observational

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

NCT06349642
View directory record Official record
Conditions
Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Liver Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Skin Neoplasm, Metastatic Malignant Solid Neoplasm, Resectable Lung Non-Small Cell Carcinoma, Early Stage Lung Non-Small Cell Carcinoma, Resectable Malignant Solid Neoplasm, Resectable Triple-Negative Breast Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Recurrent Cervical Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Malignant Skin Neoplasm, Recurrent Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Tissue Collection
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 24, 2026, 9:45 PM EDT
Recruiting Phase 2 Interventional

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

NCT06116682
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma
Interventions
Amivantamab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
Biological · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
271
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Auburn, California + 229 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 24, 2026, 9:45 PM EDT
Completed Not applicable Interventional Results available

Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR)

NCT01463423
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
iSABR, 25 Gray in 1 fraction for small peripheral tumors, iSABR, 50 Gray in 4 fractions for medium peripheral tumors, iSABR, 54 Gray in 3 fractions for large peripheral tumors, iSABR, 40 Gray in 4 fractions for small central tumors, iSABR, 50 Gray in 4 fractions for medium central tumors, iSABR, 60 Gray in 8 fractions for large central tumors
Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
2
States / cities
Stanford, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Oct 24, 2026, 9:45 PM EDT
Completed Phase 2 Interventional Results available

Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer

NCT00271505
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Bevacizumab (Avastin), Carboplatin, Docetaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Oct 24, 2026, 9:45 PM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma

NCT00435578
View directory record Official record
Conditions
Carcinoma, Small Cell Lung
Interventions
Glufosfamide
Drug
Lead sponsor
Threshold Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
3
States / cities
Greenbrae, California • Tampa, Florida • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 30, 2009 · Synced Oct 24, 2026, 9:45 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Nebulized Hypertonic Saline for Bronchiolitis

NCT00619918
View directory record Official record
Conditions
Bronchiolitis
Interventions
Nebulized 3% saline, Nebulized 0.9% saline
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
Up to 24 Months
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Los Angeles, California • Oakland, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 24, 2026, 9:45 PM EDT
Completed Phase 2 Interventional Results available

Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC

NCT00130780
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Pre-surgical Treatment with Bevacizumab plus Chemotherapy, Pre-Surgical Docetaxel and Cisplatin and Adjuvant Bevacizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2016 · Synced Oct 24, 2026, 9:45 PM EDT
Terminated Phase 1 Interventional

Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer

NCT00042835
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
cisplatin, etoposide, erlotinib hydrochloride, radiation therapy, docetaxel, paclitaxel, carboplatin, laboratory biomarker analysis
Drug · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 1, 2013 · Synced Oct 24, 2026, 9:45 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors

NCT04198818
View directory record Official record
Conditions
Advanced Tumors, Melanoma, Non-Small-Cell Lung Cancer, Erdheim-Chester Disease, Other RAS/RAF/MEK/ERK Mutated Tumors
Interventions
HH2710
Drug
Lead sponsor
Haihe Biopharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Lafayette, Indiana • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Oct 24, 2026, 9:45 PM EDT
Completed No phase listed Observational Results available

Utilizing CT Based Imaging Parameters of Body Composition to Understand Heterogeneity of Response to Biologic Therapies in Severe Asthma Cohorts

NCT06922760
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 85 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Denver, Colorado • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 24, 2026, 9:45 PM EDT
Terminated Phase 1 Interventional

Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer

NCT00937482
View directory record Official record
Conditions
Male Breast Cancer, Stage IV Breast Cancer, Stage IV Melanoma, Stage IV Non-small Cell Lung Cancer, Stage IV Renal Cell Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer, Tumors Metastatic to Brain
Interventions
cediranib maleate, whole-brain radiation therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2013 · Synced Oct 24, 2026, 9:45 PM EDT
Not yet recruiting Not applicable Interventional

Lumbar Punctures for the Detection of ctDNA in the Cerebrospinal Fluid of Patients With Stage III and IV Non-Small Cell Lung Cancer

NCT06816979
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Lumbar Puncture, Magnetic Resonance Imaging
Procedure · Device
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 24, 2026, 9:45 PM EDT
Recruiting Phase 3 Interventional

A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma

NCT07456033
View directory record Official record
Conditions
Asthma
Interventions
Depemokimab, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
16
States / cities
Little Rock, Arkansas • Newport Beach, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 24, 2026, 9:45 PM EDT
Terminated Phase 1Phase 2 Interventional

A Study of Nimotuzumab in Combination With External Radiotherapy in Non-Small Cell Lung Cancer

NCT00369447
View directory record Official record
Conditions
Non-small-cell Lung Cancer
Interventions
External radiotherapy, nimotuzumab
Procedure · Biological
Lead sponsor
YM BioSciences
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New Port Richey, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2011 · Synced Oct 24, 2026, 9:45 PM EDT
Completed Phase 1Phase 2 Interventional

A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens

NCT03953235
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Shared Neoantigen-Positive Solid Tumors
Interventions
GRT-C903, GRT-R904, nivolumab, ipilimumab
Biological
Lead sponsor
Gritstone bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
12
States / cities
Phoenix, Arizona • Santa Monica, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 24, 2026, 9:45 PM EDT
Terminated Phase 1 Interventional

Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

NCT03275597
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage IV
Interventions
Durvalumab, Tremelimumab, Stereotactic Body Radiotherapy
Drug · Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Oct 24, 2026, 9:45 PM EDT
Completed Not applicable Interventional

A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)

NCT03927820
View directory record Official record
Conditions
COPD, Asthma
Interventions
Benefits investigation
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
914 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 24, 2026, 9:45 PM EDT